Comparative Pharmacology
Head-to-head clinical analysis: COPEGUS versus FUZEON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COPEGUS versus FUZEON.
COPEGUS vs FUZEON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ribavirin is a nucleoside analogue that inhibits viral RNA synthesis by interfering with RNA capping and polymerase activity, and may also modulate immune responses.
Fusion inhibitor; binds to gp41 of HIV-1, preventing conformational changes required for fusion with host CD4+ T-cell membrane.
800 mg orally twice daily to 1200 mg orally twice daily based on body weight (≤75 kg: 800 mg; >75 kg: 1200 mg), in combination with ribavirin, for 24 to 48 weeks depending on genotype.
90 mg subcutaneously twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 120-170 hours following multiple doses, supporting once-daily dosing with prolonged viral suppression.
Terminal elimination half-life: 3.8 hours; clinically, steady-state plasma concentrations are achieved within 2-3 days with subcutaneous administration
Ribavirin is primarily eliminated renally as unchanged drug (61%) and metabolites (30%); biliary/fecal excretion accounts for ~9%.
Renal: approximately 70% as unchanged drug via glomerular filtration; fecal: <5% as metabolites
Category C
Category C
Antiviral
Antiviral